soluble T-cell receptor therapy targeting TGF beta RII (Zelluna Immunotherapy)

N/A

Report date: 2025/03/20 09:24:03

Base Information

Drug Namesoluble T-cell receptor therapy targeting TGF beta RII (Zelluna Immunotherapy)
Drug Alias NamesTCR therapy targeting a TGFbetaRII frameshift mutation (Zelluna Immunotherapy)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionTransforming growth factor beta receptor 2 modulators
TargetsTransforming growth factor beta receptor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorway
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesZelluna Immunotherapy AS
China Registration ClassN/A

Develop Information

Active CompaniesZelluna Immunotherapy AS
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A